Sun Pharma Demands Generic Cancer Drug Market Exclusivity

Law360, Los Angeles (March 1, 2013, 10:38 PM EST) -- Sun Pharmaceutical Industries Ltd. urged a District of Columbia federal judge Friday to block the U.S. Food and Drug Administration from approving any generic versions of the oncology drug Zometa until the agency decides whether to grant 180-day market exclusivity to the Indian drugmaker.

Sun Pharma was the first pharmaceutical company to file an abbreviated new drug application to patent a Zometa generic and deserves “first-filer” status, the Friday complaint says. The exclusivity on Novartis Pharmaceuticals Corp.'s three patents covering its uses of zoledronic acid —...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

SUN GLOBAL FZE et al v. SEBELIUS et al


Case Number

1:13-cv-00277

Court

District Of Columbia

Nature of Suit

Other Statutory Actions

Judge

Amy Berman Jackson

Date Filed

March 1, 2013

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.